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a  b  s  t  r  a  c  t
Background:  Staphylococcus  aureus  is a  common  cause  of  healthcare-acquired  morbidity  and  mortality
and  increased  healthcare  resource  utilization.  A prophylactic  vaccine  is being  developed  that  may  reduce
this disease  burden.
Methods: Volunteers  in  good  general  health  aged  50–85  (n = 312)  and 18–24  (n =  96)  years  were  random-
ized  to  receive  a single  intramuscular  dose of one  of three  dose  levels  of  a  non-adjuvanted,  3-antigen  S.
aureus  vaccine  (SA3Ag)  or placebo.  SA3Ag  antigens  included  capsular  polysaccharides  5 and  8 (CP5  and
CP8),  each  conjugated  to  cross-reactive  material  197  (CRM197),  and  recombinant  clumping  factor  A (ClfA).
Safety, tolerability,  and  immunogenicity  were  evaluated.
Results:  At day  29  post-vaccination,  robust  immune  responses  were observed  in  both  age  cohorts  at  all
three  SA3Ag  dose  levels.  In  the  primary  analysis  population,  the  50- to 85-year  age  stratum,  geometric
mean-fold-rises  in competitive  Luminex® immunoassay  antibody  titers  from  baseline  ranged  from  29.2
to 83.7  (CP5),  14.1  to 31.0  (CP8),  and  37.1  to 42.9  (ClfA),  all  (P < 0.001)  exceeding  the  pre-deﬁned  two-
fold  rise  criteria.  Similar  rises  in  opsonophagocytic  activity  assay  titers  demonstrated  functionality  of
the  immune  response.  Most  injection-site  reactions  were  mild  in  severity  and  there were  no  substantial
differences  (SA3Ag  vs. placebo)  with  regard  to systemic  or adverse  events.
Conclusions:  In  this  study  of  healthy  adults  aged  50–85  and  18–24  years,  SA3Ag  elicited  a rapid  and  robust
immune  response  and  was  well  tolerated,  with  no  notable  safety  concerns.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AE, adverse event; ClfA, clumping factor A; cLIA, competitive Lumine
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ITT,  modiﬁed intention to treat; MntC, manganese transporter C; MRSA, methicillin-res
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. Introduction
Staphylococcus aureus is a leading cause of infection-related
orbidity and mortality [1–3] and is the most frequent cause
f post-operative infection [4,5]. The emergence of antibiotic-
esistant strains has impeded S. aureus disease management
6,7]. During 2011–2012, 1734 cases of S. aureus bacteremia
ere reported in Australian public hospitals, of which 24% were
ethicillin-resistant (MRSA) [8]. In the USA, studies have shown
he annual incidence of S. aureus bacteremia to be 15–17 per
00,000 population, of which nearly half are due to MRSA
9,10].
The complexity of S. aureus virulence mechanisms has made
rophylactic vaccine development challenging. To date, two clinical
accine programs that targeted single S. aureus virulence mecha-
isms have failed in development [11–16]. Based on the premise
hat a successful prophylactic S. aureus vaccine must address a com-
ination of well-conserved virulence factors expressed by most
trains, and generate antibodies that effectively kill the organism,
 multi-antigen vaccine candidate targeting the bacterial capsular
olysaccharide type 5 (CP5), capsular polysaccharide type 8 (CP8),
lumping factor A (ClfA), and manganese transporter C (MntC)
s under development [17]. S. aureus bacteria produce capsular
olysaccharides (CPs) to evade the host’s immune system [18].
ll S. aureus strains possess the genetic pathway for synthesis
f either CP5 or CP8 [19]. Analysis of CP expression shows that
lthough some strains do not express CP under in vitro growth
onditions, CP expression is detected in vivo [20,21]. ClfA is a well-
onserved surface antigen that facilitates S. aureus infection by
inding to ﬁbrinogen, complement proteins, and platelets, thus
ediating adhesion to host tissues [22]. MntC enables manganese
cquisition, which is used by S. aureus to facilitate survival in
eutrophils [23]. Preclinical studies have demonstrated efﬁcacy
f these antigens in several animal models of infection [24,25].
ntisera raised to these antigens generated robust antibody titers
hat killed S. aureus or neutralized the function of the antigen
26,27]. This ﬁrst-in-human phase I study evaluated the safety,
olerability, and immunogenicity of a vaccine formulation compris-
ng three of the four target antigens (3-antigen S. aureus vaccine
SA3Ag]): CP5 and CP8 individually conjugated to cross-reactive
aterial 197 (CRM197) – a non-toxic mutant form of diphtheria
oxin (CP5-CRM197 and CP8-CRM197) – and a recombinant mutant
orm of clumping factor A (rClfAm).  In recognition of the increased
urden of invasive S. aureus disease in older individuals [4] and
ower immune responses to vaccines commonly observed with
geing [28], healthy adult volunteers aged 18–24, as well as those
0–85 years, were evaluated. The primary objectives of this study
ere to assess immunogenicity of escalating dose levels of SA3Ag




Study participants were recruited from the community at ﬁve
tudy centers in Australia. Exclusion criteria prohibited any major
llness that increased risk associated with study participation, preg-
ancy (tested prior to vaccination), breastfeeding, any coagulation
r bleeding time disorder (low-dose daily aspirin allowed), con-
raindication to vaccine components, known immunodeﬁciency,
eceipt of blood products or immunoglobulins within 12 months,
revious S. aureus vaccination, and participation in any other inves-
igational trial. Participants with stable chronic conditions were
ligible for inclusion provided these conditions were being treated (2015) 1846–1854 1847
and were medically stable as determined by the investigator. The
study was  approved by the Human Research Ethics Committee
of each participating institution. All participants provided written
informed consent prior to undergoing any study-related proce-
dures.
2.2. Study design
In this ﬁrst-in-human, phase I, participant- and investigator-
blinded, sponsor-unblinded, ascending dose level, randomized,
placebo-controlled study, SA3Ag was administered as a non-
adjuvanted, lyophilized vaccine containing 10 g each of CP5- and
CP8-CRM197 conjugates and 20 g of rClfAm (low-dose level), 30 g
of CP5- and CP8-CRM197, and 60 g of rClfAm (mid-dose level),
or 100 g of CP5- and CP8-CRM197 and 200 g of rClfAm (high-
dose level), reconstituted with 60 mM NaCl. The saline placebo
contained 150 mM (isotonic) NaCl. Randomization within each
SA3Ag dose level cohort (low, mid, and high) was  3:1 active
to placebo, such that overall, randomization was approximately
1:1:1:1 (low:mid:high:placebo). Dosing was administered in a
step-wise manner, with sentinel safety cohorts of 12 participants
dosed ﬁrst, starting with the low-dose-level cohort (18–24- and
50–64-year age substrata). Subsequent dosing proceeded follow-
ing evaluation of safety data of the sentinel safety cohorts by a
project-independent safety review team. An unblinded dispenser
randomized participants through use of an interactive website or
voice-response system. Vaccine was administered to participants
in a blinded manner by study staff.
2.3. Safety evaluation
Local injection-site reactions (erythema, induration, and pain)
and systemic events (vomiting, diarrhea, headache, fatigue, mus-
cle pain, joint pain, and fever) were recorded by participants
in an electronic diary (e-diary) from day 1 through day 14 fol-
lowing vaccination. Laboratory assessments were performed in
sentinel participants prior to vaccination and at days 5 and 15,
including complete blood count, platelet aggregation assay, ﬁbrin-
ogen activity assay, prothrombin time, international normalized
ratio, partial thromboplastin time, total hemolytic complement
(CH50) and complement component 3 levels, and examination
of urine sediment for white and red blood cell casts. Adverse
events (AEs) were recorded for at least 28 days after vaccination,
and serious adverse events (SAEs) and newly diagnosed chronic
medical disorders for 6 months following vaccination. Investiga-
tors assessed each AE to determine severity and relatedness to
vaccine.
2.4. Immunogenicity evaluation
Blood samples were collected prior to vaccination (day 1; the
day of vaccination) and at each post-vaccination visit (days 5,
8, 11, 15, and 29; and months 2 and 3). Antigen-speciﬁc serum
immune responses were measured using a multiplex competitive
Luminex® immunoassay (cLIA) that measures the ability of serum
immunoglobulin to compete with the binding of antigen-speciﬁc
monoclonal antibodies (mAbs) to each antigen coated on beads
[29]. The cLIA for ClfA utilized a functional competitive mAb previ-
ously shown to inhibit S. aureus binding to host ﬁbrinogen [26]. The
ability of SA3Ag to induce functional antibodies that kill S. aureus
clinical isolates that express either CP5 (S. aureus PFESA0186) or
CP8 (S. aureus PFESA0158) was  measured using an opsonophago-
cytic activity (OPA) assay [27]. The OPA assay titer is calculated as
the highest serum dilution at which serum antibodies facilitate the
killing of 50% of the bacteria added to the assay in the presence of
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as used as an exogenous complement source in the OPAs. HL-
0 cells (Catalog no. CCL240, ATCC, USA) were differentiated with
imethylformamide and used as a source of phagocytic cells in the
PAs. Samples from all time points were tested using the cLIA assay,
nd samples from a randomly selected subset of participants in each
ose level cohort and age substrata (n = 22–32) were tested using
he OPA assay at baseline and post-vaccination days 15 and 29, and
onth 3.
.5. Sample size and statistical analysis
Sample size for the 18–24-year age stratum was estimated based
n safety evaluation. With 28 participants per SA3Ag vaccine group,
here was at least 90% power to detect an event with 60% incidence
n the vaccine group when the rate in the placebo group was no
ore than 10%, using a one-sided Fisher’s Exact test at the 2.5%
evel. Allowing for a 12% dropout rate, 32 participants were needed
er vaccine group.
Sample size for the 50–85-year age stratum was based on
ypothesis testing of antibody geometric mean titers (GMTs) from
reclinical animal studies. With 64 participants per SA3Ag vaccine
roup, there was an estimated 93.4% power per antigen to detect
 two-fold increase in GMT  relative to baseline using a one-sided
aired t-test at the 2.5% level. Allowing for a drop-out of 18%, 78
articipants were needed per vaccine group to achieve 81% power
or all three antigens.
Analyses of the proportions of participants reporting local reac-
ions and systemic events through post-vaccination day 14 were
ummarized descriptively. The primary immunogenicity analysis
opulation was the modiﬁed intention to treat (mITT) population.
he primary end point was antigen-speciﬁc geometric mean-fold-
ise (GMFR) in cLIA titer from baseline (Visit 1) to post-vaccination
ay 29 (Visit 6) in the 50–85-year age stratum. The primary com-
arison of interest was a two-fold GMFR for each antigen. As the
ample size is large enough to utilize parametric statistics, the one-
ample (1-sided) t-test was used to compare GMFR with a two-fold
ncrease in cLIA titer at a 2.5% level of signiﬁcance. cLIA and OPA
iters were descriptively summarized at each time point assessed.
Fig. 1. Study  (2015) 1846–1854
3. Results
3.1. Participants
A total of 408 consenting participants were randomized into
four groups (102 participants per vaccination group, each com-
prising 78 participants aged 50–85 years and 24 participants aged
18–24 years) (Fig. 1). Generally, demographic characteristics were
comparable among vaccine groups in the 50–85-year age stratum
(Supplementary data: Table 1).
All participants received study vaccination, except for one par-
ticipant in the mid-dose-level group assessed as ineligible after
randomization but prior to vaccination (due to receipt of a prohib-
ited medication) and one participant in the high-dose-level group
who withdrew consent prior to vaccination. In total, 406 partici-
pants were vaccinated. One additional participant withdrew before
day 29 due to refusal to undergo additional blood draws. A total of
392 participants completed the month 6 visit.
3.2. Immunogenicity evaluation
Pre-vaccination cLIA GMTs ranged from 57 to 228 for CP5, 81 to
154 for CP8, and 25 to 27 for ClfA across all dose levels/age strata.
For the majority of participants, cLIA titers to ClfA were below the
limit of quantiﬁcation at baseline (93.1–96.1% of participants across
all dose levels/age strata). Substantial increases in cLIA GMTs from
baseline to day 29 were observed for all three antigens at all vaccine
dose levels and in each age stratum (Fig. 2). GMFRs from baseline to
day 29 levels ranged from 29.2 to 83.7 for CP5, 14.1 to 31.0 for CP8,
and 37.1 to 42.9 for ClfA in subjects aged 50–85 years. These results
greatly exceeded the pre-speciﬁed two-fold increase in cLIA titer
(P < 0.001). A dose–response relationship was  observed for CP5 and
CP8 in the 50–85-year age stratum as measured by both cLIA and
OPA assays (Figs. 2 and 3). ClfA cLIA responses were similar across
the SA3Ag vaccine dose levels.
The kinetics of the antigen-speciﬁc cLIA GMTs until the month 3
post-vaccination visit for the 50–85- and 18–24-year age strata are
shown in Fig. 4. A rapid rise in GMTs was  observed, with anti-CP5
and anti-CP8 antibodies reaching a peak between day 11 and day 15
for all dose levels and in both age strata. ClfA GMTs also rose rapidly,
proﬁle.
M. Nissen et al. / Vaccine 33 (2015) 1846–1854 1849
Fig. 2. Antigen-speciﬁc antibody titers at day 29 post-vaccination by age group using the cLIA assay.
cLIA:  competitive Luminex® immunoassay; rClfAm: recombinant mutant form of clumping factor A; GMT: geometric mean titer; CP5-CRM197: capsular polysaccharide type
5–cross-reactive material 197; CP8-CRM197: capsular polysaccharide type 8–cross-reactive material 197.
1850 M. Nissen et al. / Vaccine 33 (2015) 1846–1854
Fig. 3. Functional antibody titers at day 29 post-vaccination: OPA assay by age group.
OPA: opsonophagocytic activity; CP5-CRM197: capsular polysaccharide type 5–cross-reactive material 197; GMT: geometric mean titer; CP8-CRM197: capsular polysaccharide
type  8–cross-reactive material 197.
M. Nissen et al. / Vaccine 33 (2015) 1846–1854 1851
Fig. 4. Kinetics of immune response through 3 months using the cLIA assay.
































f–cross-reactive material 197; CP8-CRM197: capsular polysaccharide type 8–cross-
eaching a peak between day 15 and day 29. GMTs waned gradually,
emaining substantially higher at month 3 compared with baseline.
Pre-vaccination OPA GMTs ranged from 203 to 666 and from 589
o 1145 across all dose levels/age strata using OPA assays with the
P5- and CP8-expressing S. aureus clinical isolates, respectively. The
ajority of participants had measurable pre-existing OPA titers.
erum from participants vaccinated with either low-, mid-, or high-
ose-level SA3Ag had substantially increased opsonophagocytic
illing activity against CP5- and CP8-expressing S. aureus strains
s demonstrated by post-vaccination day 29 OPA titers compared
ith baseline titers (Fig. 3). No increases in GMTs were seen in
he placebo group. CP5 and CP8 OPA GMFRs in the 50–85-year age
tratum at day 29 ranged from 15.4- to 73.5-fold and from 13.9-
o 34.7-fold, respectively. OPA GMT  responses through month 3
howed a similar pattern to those of cLIA GMT  responses (data not
hown).
.3. Safety results
The most common local reaction in all age groups was
njection-site pain, reported more frequently by participants in
he high-dose-level SA3Ag vaccine group (Fig. 5), and by partic-
pants aged 18–24 years. Injection-site reactions were generally
ild in severity. In the 50–85-year age stratum, incidences of red-
ess and swelling were higher with increasing SA3Ag dose level.
nset of local reactions tended to occur within the ﬁrst 2 days
ost-vaccination among participants aged 18–24 years, whereas
lder participants in the mid- and high-dose-level SA3Ag groups
ore often reported local reactions with onset between 6 to 8 days
ost-vaccination.
Frequencies of systemic events reported among the 50–85-year
ge stratum were generally comparable between the placebo
52.6%) and SA3Ag vaccine groups (44.9–61.0%), with no dose rela-
ionship observed (Fig. 6). Frequencies of systemic events reported
mong participants aged 18–24 years were generally higher than
or the older age stratum, but the incidences were again comparablee material 197.
between the placebo and SA3Ag vaccine groups. The majority of
systemic events among both age strata were mild in severity, with
the duration being generally comparable among dose-level groups.
Proportions of participants reporting AEs were comparable
among placebo (52.9%) and the low- (52.0%), mid- (51.5%), and
high-dose-level (61.4%) SA3Ag vaccine groups. High-dose-level
SA3Ag recipients reported signiﬁcantly more related AEs (28.7%),
according to the investigator’s causality assessment than par-
ticipants in the placebo group (11.8%; P < 0.01). These largely
comprised local reactogenicity events not captured via e-diary, and
therefore reported as AEs. Most AEs were mild or moderate in
severity. The proportion of participants reporting severe AEs was
low overall, and there were no apparent differences among placebo
(3.9%) and SA3Ag vaccine groups (4.0–5.0%). None of the SAEs
reported during the study were considered related to the inves-
tigational vaccine. Two participants, both in the 65–85-year age
substratum, reported SAEs up to day 29 after vaccination: a placebo
recipient reported pyelonephritis, and a mid-dose-level SA3Ag vac-
cine recipient with a background history of recurrent elbow bursitis
developed cellulitis of the elbow; no causative agent of cellulitis
was identiﬁed. Twelve participants reported SAEs between day 29
and month 6. All SAEs occurred in the 50–85-year age stratum,
with the exception of one SAE reported after day 29 (tonsillitis in a
placebo recipient). No deaths occurred during the study.
One high-dose-level SA3Ag vaccine recipient was  withdrawn
due to an AE considered related to the investigational product
(injection-site erythema and swelling on day 2 measuring 14.5 cm
and 13 cm,  respectively). Swelling resolved by day 7; however, red-
ness took 36 days to completely resolve.
A total of six participants were withdrawn due to unrelated AEs
or SAEs: two  mid-dose-level SA3Ag vaccine recipients due to non-
small-cell lung cancer and chronic obstructive pulmonary disease,
respectively, and four placebo recipients.
Laboratory test results were comparable at baseline, day 5,
and day 15. Reported laboratory abnormalities were sporadic and
generally similar among placebo and SA3Ag vaccine groups. No















dFig. 5. Local injection-site reactions within 14 days of vaccination.
ncrease in frequency or severity of laboratory abnormalities with
ncreasing SA3Ag vaccine dose level was identiﬁed.
. Discussion
The development of a safe and efﬁcacious vaccine could reduce
he substantial burden of S. aureus disease; however, so far, sev-
ral attempts to do so have been unsuccessful [30]. In contrast
o previous vaccine candidates, SA3Ag targets a combination of
. aureus virulence mechanisms involved in S. aureus pathogeni-
ity. First-in-human study results for this investigational vaccine
emonstrate well-characterized functional immune responses to
he three antigens. By comparison, previous candidate vaccines
ave only shown generation of anti-staphylococcal binding anti-
odies using ELISA [11], and only demonstrated bacterial uptake
y phagocytic cells [14], rather than killing of S. aureus in OPA
ssays [14,15]. Both antibody- and cell-mediated mechanisms were
emonstrated in protection against recurrent S. aureus infection (2015) 1846–1854
in a murine model of skin and soft tissue infection [31]; how-
ever, the importance of bacterial killing following phagocytosis
is supported by the observation that opsonophagocytic killing by
neutrophils serves as a primary clearance mechanism for S. aureus
infection, as evidenced by the high incidence of S. aureus dis-
ease in neutropenic patients and those with genetically-impaired
neutrophil function (e.g., leukocyte adhesion deﬁciency or chronic
granulomatous disease that result in defective neutrophil killing of
S. aureus)  [32].
OPA assays that measure the killing of S. aureus clinical isolates
were, therefore, developed to demonstrate that SA3Ag could elicit
antibodies that kill S. aureus clinical isolates expressing either CP5
or CP8 [27]. Humans are constantly exposed to S. aureus through
colonization and in some cases disease. Consequently, most indi-
viduals have positive binding antibody responses to many S. aureus
cellular components [33]. In most cases these responses are not
functional but some individuals can exhibit low functional anti-
body titers to some antigens [34] as observed in our study and as
exempliﬁed by the low levels of functional antibodies to capsular
polysaccharides that are measured in OPA. After vaccination with
SA3Ag, OPA GMTs increased >10-fold at day 29. Although a recent
preclinical study hypothesized that CP-speciﬁc antibodies are not
effective at killing S. aureus in the presence of other antibodies that
bind to S. aureus cell surface components [35], this ﬁnding was
not observed in our study. Likewise, we  sought to demonstrate
that rClfAm could generate functional antibodies. As the mecha-
nism for ClfA virulence is via binding to host ﬁbrinogen [36], a
mAb  previously shown to inhibit S. aureus binding to ﬁbrinogen
[26] was  utilized in the ClfA cLIA assay, to determine whether
SA3Ag-generated antibodies could compete with this inhibitory
mAb. While most participants did not demonstrate ClfA cLIA titers
prior to vaccination, substantial responses were observed after
SA3Ag vaccination. The existence of background ClfA-binding anti-
bodies due to natural S. aureus exposure has been well documented
[26,33,34,37,38]. In this study, we demonstrated using an indirect
functional assay that humans do not have pre-existing functional
titers to ClfA that can inhibit the binding of S. aureus to ﬁbrino-
gen. However, a ClfA containing vaccine can elicit such a functional
response after a single dose.
Single-dose administration of this non-adjuvanted SA3Ag vac-
cine was well tolerated, with an acceptable safety proﬁle at all three
dose levels. Local reactions following vaccination were reported
more frequently with increasing dose level; however, most were
mild or moderate and generally resolved within 3 days. The onset
of local reactions was  notably different between the two age strata,
with reactions generally reported within 2 days in participants
aged 18–24 years, and within 6 to 8 days in participants aged
50–85 years. Systemic events following vaccination were compa-
rable among placebo and SA3Ag vaccine groups, the majority of
which were mild in severity.
Importantly, acceptable safety and tolerability, and compara-
bly robust immune responses, were seen among older and young
adults. The rapid rise to peak antibody titers following SA3Ag
vaccination suggests an anamnestic response to the S. aureus
antigens, possibly as a result of prior natural exposure to the
organism. The kinetics of the immune response through at least
3 months following SA3Ag vaccination, targeting a combination of
pathogenic mechanisms, give conﬁdence for potential vaccine util-
ity in patients entering a period of high risk of S. aureus disease,
such as those preparing to utilize healthcare systems [39].
The substantial immune responses, taken in combination with
the acceptable safety and tolerability, led to selection of the
mid-dose-level SA3Ag vaccine antigens (30 g CP5-CRM197, 30 g
CP8-CRM197, and 60 g rClfAm) for further clinical development.
A 4-antigen vaccine formulation (SA4Ag) currently under devel-
opment includes the SA3Ag antigens at this selected dose level in










dFig. 6. Participants reporting system
ombination with an additional antigen, the bacterial manganese
ransport protein (MntC) [17,40].
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